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1. Introduction 
1.1 Definition and clinical characteristics 
Mantle Cell Lymphoma (MCL) is a relatively rare type of mature B-cell lymphoma that 
comprises 5% of Non-Hodgkin’s Lymphomas(NHL)1-3. MCL was added to the Revised 
European–American Lymphoma classification in 1994. Having both indolent and incurable 
features associated with aggressive clinical course, MCL is most frequently seen in 6th 
decade of life, with male dominance 3 to 4:12. Malignant origin of MCL cells appear to 
derive from an antigen-naive pregerminal center cell4, 5. 
 
1. B-cell neoplasms 
1. Precursor B-cell 
2. Mature B-cell 
Chronic lymphocytic leukemia/small lymphocytic lymphoma 
Lymphoplasmacytic lymphoma 
Splenic marginal zone lymphoma 
Extranodal marginal zone B-cell lymphoma of MALT 
Nodal marginal zone B-cell lymphoma 
Follicular lymphoma 
Mantle cell lymphoma
Diffuse large B-cell lymphoma 
Mediastinal (thymic) large B-cell lymphoma 
Intravascular large B-cell lymphoma 
Primary effusion lymphoma 
Burkitt's lymphoma/leukemia 
3. B-cell proliferations of uncertain malignant potential 
2. T-Cell and NK-Cell neoplasms 
Table 1. World Health Organization Classification of Lymphomas1. 
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At the time of diagnosis, patients tend to have more extranodal disease and low serum 
albumin6. Although MCL has differential diagnosis with Chronic Lymphocytic Leukemia 
(CLL) and low-grade NHL, mimicking malignancies with indolent behavior, it follows an 
aggressive course with 10% to 15% long-term survivors7 despite administration of standard 
chemotherapy courses commonly used in NHLs8, corresponding to a median survival of 3 
to 5 years.  
2. Diagnosis 
Diagnosis of MCL can be made by lymph node or bone marrow biopsy, or analysis of 
malignant cells obtained from peripheral blood, if the disease is in the leukemic phase9, 10. 
Differential diagnosis with CLL is important since both MCL and CLL cell have co-
expression of CD5 and CD19/2011. Malignant cells are negative for CD10, CD23 and BCL6. 
Although absence of CD23 antigen expression on malignant cell population strongly favor a 
diagnosis of MCL12, 13, presence of cyclinD1 expression by immunohistochemical staining14 
or determination of t(11;14) translocation by molecular analysis15-18 is required to confirm 
the diagnosis19. Cyclin D1 is overexpressed in MCL as a result of the landmark 
t(11;14)(q13;q32) translocation20. Cyclin D1 complex with cyclin dependent kinases 4 and 6 
(Cdk4 and Cdk6) and cyclin E-Cdk2, leading to phosphorylation of retinoblastoma protein 
(Rb), irreversibly inducing progression of the cell from G1 to S phase, which is not the only 
biologic dysregulation on the way to malignant transformation21-24. 
 
Disease CD5 CD10 CD23 CD43 Cyclin D1 Ig class 
FL - + +/- - - IgM, IgG 
MCL + - - + + IgM/IgD 
CLL/SLL + - + + - IgM/IgD 
LPL - - - +/- - IgM (c) 
MALT - - - +/- - IgM (c, s) 
SMZL - - - - - IgM/IgD 
HCL - - - - -/+ IgG 
FL, follicular lymphoma; MCL, mantle cell lymphoma; CLL/SLL, chronic lymphocytic leukemia/small 
lymphocytic lymphoma; LPL, Lymphoplasmacytic lymphoma; MALT, marginal zone lymphoma of 
MALT type; SMZL, splenic marginal zone lymphoma; HCL, hairy cell leukemia; Ig class, most 
commonly expressed heavy chain classes; c, cytoplasmic Ig; s, surface Ig. 
Table 2. Differential Diagnosis of “Small” B-Cell Lymphomas25. 
3. Prognostic parameters 
Prognosis can be estimated by using MIPI (mantle cell lymphoma international prognostic 
index, Figure 1)26 which seems to be more efficient than international prognostic index 
(IPI)27 or follicular lymphoma international prognostic index (FLIPI)28, 29, which includes 
leukemic phase10, 30, 31, besides other clinical parameters used in the IPI.  
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Table 3. Simplified MIPI26. 
For each prognostic factor, 0 to 3 points were given to each patient and points were 
summed up to a maximum of 11. Patients with 0 to 3 points in summary were classified as 
low risk, patients with 4 to 5 points as intermediate risk, and patients with 6 to 11 points 
as high risk. 
 
 
Fig. 1. Overall survival according to the mantle cell lymphoma international prognostic 
index (MIPI). 
Although Ki-67 has previously been shown to predict prognosis (Figure 2)32-34, analysis of 
Ki-67 did not substantially change the regression coefficient of the MIPI score and served as 
an important biologic marker with strong additional prognostic relevance26.  
Recently, proliferation gene expression signature has been reported to be the best molecular 
predictor of survival in patients with MCL21, leading to a prognostic model defined as an 
optimized survival predictor composed of five genes: RAN, MYC, TNFRSF10B, POLE2, and 
SLC29A235. Furthermore, this model was validated for application in formalin-fixed 
paraffin-embedded tissue samples and appeared superior to the immunohistochemical 
marker Ki-6735.  
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Fig. 2. Overall survival of patients with MCL according to Ki-67 proliferation index33. 
4. Role of chemotherapy 
When it comes to assessment of long term overall survival, MCL has the worst prognosis 
among all lymphoma types36, a watch-and-wait strategy should be avoided. Retrospective 
analyses of administration of standard chemotherapy have not shown any improvement in 
overall survival in patients with MCL6, 37. Most regiments induce around 80% response rates 
with complete remissions up to 30% of cases6, 8. While more aggressive regimens were 
used38, reliable cure rates with conventional treatment has not been reported until now36.  
Compared to historical controls, median survival with conventional chemotherapy CVP and 
CHOP have not been improved37. In a randomized trial, these two regimens were associated 
with similar response rates (84% and 89%) and median overall survivals (32 and 37 
months)39. Only one third of patients with untreated40 or relapsed41 MCL will respond to 
rituximab as single agent.  Rituximab may also be used for purging tumor cells either with 
standard chemotherapy42 or prior to high dose therapy regimens with stem cell support43. 
But in a randomized trial, addition of rituximab to CHOP regimen failed to improve overall 
survival (Figure 3)44. Maintenance interferon-alfa therapy following induction regimen has 
not been proven to improve survival either45, 46. 
Fludarabine can also be used in patients with lymphoma with or without rituximab 
combination47. Fludarabine alone in previously treated MCL can induce temporary 
responses in a third of patients lasting between 4 to 8 months48. In newly diagnosed 
patients, fludarabine appears to be more active, inducing responses in 60% , half of  which is 
complete response49. Combining fludarabine with idarubicin or cyclophosphamide may 
improve induction of complete responses50, 51. Fludarabine and cyclophosphamide 
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combination(FC)  can induce a higher response rate of 63% in patients recurrent MCL51. 
Previously untreated patients have response rate up to 100% with a complete response rate 
of 70% and 28 months of progression free survival51.  
 
 
Fig. 3. Progression-free survival after cyclophosphamide, doxorubicin, vincristine, and 
prednisone (CHOP) and rituximab and CHOP (R-CHOP)44. 
In a randomized study testing addition of rituximab to fludarabine, cyclophosphamide and 
mitoxantrone (FCM), patients in the rituximab arm were found to have significant 
improvement in disease free and overall survival52-54. Fludarabine combined with 
cyclophosphamide and rituximab is a highly effective regimen in patients relapsing from 
previously received CHOP regimen55.  Addition of rituximab to the chemotherapy regimens 
does not appear to increase toxicity56. 
Although tolerating patients treated with the hyper-CVAD regimen had excellent response 
and survival rates of greater than 90% at 3 years and 4.6 years of time to treatment failure 
(TTF at 8yr , 16% if age>65, 46% if age<65) following 10 year observation period7, 38, 57, 58, 
patients treated with conventional therapies have also reported to have similar 3 year 
survival rates59, 60. The hyper-CVAD regimen without stem cell transplantation was not 
associated with a plateau in the survival curves (Figure 4)57.  In this study, beta-2-
microglobulin levels and IPI/MIPI scores were found to predict survival57. Hyper-CVAD 
regimen data may suggest high efficacy of the high-dose Ara-C (HIDAC) regimen, which 
needs to be tested in further clinical trials. 
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Fig. 4. Overall survival and time to failure in 97 patients treated with R hyper-CVAD 
alternating with R M/A57. 
Due to advanced age at the time of presentation of MCL, there is a concern about intensive 
therapy regimens being associated with higher toxicity rates requiring patient selection and 
patients tolerating intensive therapies are being selected for high-dose therapies with stem 
cell support. 
5. New agents 
Recently, bortezomib61-63, lenalidomide64-66, bendamustine67-69, pixantrone70, azaepothilone 
ixabepilone71 and mTOR inhibitor temsirolimus72-74 has been shown to demonstrate activity 
alone and in combination with rituximab and mitoxantrone, and may induce complete 
responses in relapsed or refractory MCL61, 64, 69, 75, 76. Along with rituximab, these biotherapy 
agents can be used frontline or may also be introduced into post transplant maintenance to 
prevent or treat relapses61, 68, 77-81. There may be an advantage of combining rituximab with 
bendamustine compared to combining with the conventional CHOP regimen in terms of 
disease free survival82. Recently, it was reported that frontline use of cladribine and 
rituximab can induce an overall response rate of 87%, with 61% of patients achieving 
complete remission, suggesting use of this combination for the initial treatment of MCL83. 
Radioimmunotherapy with 90Y-labeled anti-CD20 monoclonal antibody (ibritumomab 
tiuxetan) or 131I-rituximab is now being tested in phase I-II trials, including stem cell 
transplant setting84-87.  
6. High dose chemotherapy with autologous stem cell support (ASCT) 
Since conventional and dose intense chemotherapy regimens have failed to induce cure or a 
plateau phase in time to treatment failure curves, high dose therapy with autologous stem 
cell support have been studied in the relapse setting88 as well as consolidating complete 
responses following frontline chemotherapy regimens88-94.  
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In a randomized trial testing ASCT versus IFN-alfa consolidation following response to 
CHOP or CHOP like regimens with or without rituximab, consolidation with BEAM/ASCT 
improved progression free survival (PFS) but has not been shown to improve overall 
survival (OS)(Figure 5)93. When patients responding to R-CHOP regimen received HIDAC 
therapy followed with autologous tranplantation with the BEAM regimen, also a plateau 
was not observed in time to treatment failure (TTF) and OS curves94. 
 
 
Fig. 5. Progression-free survival after high-dose radiochemotherapy followed by ASCT and 
IFN-alfa maintenance in MCL93. 
Autologous transplantation with conventional conditioning regimens without in vivo 
purging induced a median survival of 47 months88. Analysis of this patient group did not 
reveal a plateau in the survival curve88.  
Addition of rituximab to ASCT regimen leads to better event free survival (EFS) curves in 
patients with first remission, not affecting progression in patients with relapsed/refractory 
disease91. 
The R-HDS regimen consisting of high-dose sequential chemotherapy (including 
intravenous administration of high-dose cyclophosphamide, high-dose cytarabine, high-
dose melphalan, and high-dose mitoxantrone plus melphalan) and in vivo purging with 
rituximab resulted in OS and EFS rates at 54 months were 89% and 79%, respectively96. 
These results compare favorably with the 42% OS rate and the 18% EFS rate observed in 35 
age-matched historic controls treated with standard-dose chemotherapy at the participating 
centers (Figure 6)96. 
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Fig. 6. Overall survival for mantle cell lymphoma patients after autologous transplantation 
without in vivo purging88. 
 
 
Fig. 7. EFS following ASCT after myeloablative therapy with (broken line) or without 
peritransplant rituximab (solid line)95. 
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Fig. 8. PFS for patients receiving ASCT for relapsed/refractory disease91.  
 
 
Fig. 9. Overall survival and event-free survival of patients treated with R-HDS versus 
conventional chemotherapy96. 
Heavily treated patients with multiple recurrences may undergo an effective salvage with 
high-dose radioimmunotherapy (RIT) coupled with autologous stem cell support97. 
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Fig. 10. OS and PFS obtained in patients with relapsed MCL treated with 131I-tositumomab, 
etoposide, cyclophosphamide, and ASCT97. 
7. Allogeneic transplantation for achieving cure 
Myeloablative or non-myeloablative allo-HSCT is generally performed in patients with 
lymphoma relapsing following auto-HSCT, since patients need tumor-free grafts that can 
induce a graft-versus-lymphoma (GVL) effect. 
Physicians should consider the need for an allogeneic transplant when there is a need for a 
GVL effect (high risk of relapse) which can be predicted by the presence of; 
 A high MIPI score 
 Aggressive clinical behavior characterized by not achieving a satisfactory response to 
chemotherapy regimens 
 remaining PET positive following ASCT98 
 Multiple relapses 
and; 
 If the patient is young (<55 years) or, 
 Autologous stem cells cannot be mobilized 
in patients considered to be eligible following pretransplant screening tests.  
Evidence for presence of graft versus lymphoma (GVL) effect has been reported in patients 
with MCL who underwent allo-HSCT99. CVL effect may be observed as conversion to pcr 
negativity for t(11;14) or achieving CR in the presence of GVHD99, or observing lower 
relapse rates in allo-HSCT recipients compared to patients undergoing autologous 
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transplantation100-102. A healthy comparison of autologous and allogeneic transplants cannot 
be made at present, due to lack of randomized trials and the different prognostic groups 
undergoing  each transplant type. By using myeloablative regimens for relapsed patients, 
allogeneic transplants can induce three year event free survivals (EFS)around 50%99, 101-104. 
However, if performed in first CR or PR, EFS induced by allo transplants at three years can 
be as high as 70%103. 
 
 
 
 
 
 
 
 
 
 
Fig. 11. Event-free survival according to type of BMT103. 
8. Reduced intensity allogeneic stem cell transplantation 
In the allogeneic transplant setting, benefit of cure over transplant related mortality can be 
positively affected by using reduced intensity (RIC) or non-myeloablative (NMA) 
conditioning regimens105-116. Using donor lymphocyte infusions for GVL effect in patients 
undergoing allogeneic transplantation with RIC or NMA regimens, low transplant 
mortality rates (<10%) and higher OS (73 to 85%)  and EFS rates (73 to 82%) can be 
achieved105, 117, 118. 
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Fig. 12. Kaplan-Meier overall survival (OS) and current progression-free survival (CPFS) 
accounting for salvage post-DLI in with relapsed MCL who received NMA allogeneic 
transplantation105. 
 
 
Fig. 13. Favorable overall survival following reduced intensity allogeneneic  transplants by 
disease group117. 
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9. Decision making for transplant options 
While standard chemotherapy regimens do not offer long term progression free survival, 
intensive therapy followed by ASCT should be considered for each newly diagnosed 
patient92, especially if the MIPI score is translating into poor prognosis. 
Multiply relapsed patients will not do well after autologous transplants91, 103. Best time to 
perform an autologous transplant is following CR91, 92, 119, 120 obtained after high-dose 
therapy with hyperCVAD or HDS regimen, coupled with rituximab91, including in vivo 
purging prior to stem cell collection81, 92, 96. With this approach, patients eligible for these 
sequential intensive regimens may enjoy long term disease free survival, although cure 
cannot be achieved121. 
 
 
Fig. 14. Event-free survival according to remission status at BMT103. 
Newly diagnosed and relatively younger patients less than 60 years of age who are not 
eligible for ASCT or relapsing after ASCT, or patients with recurrence following 
chemotherapy, can still be cured by allogeneic SCT following an effective salvage regimen 
inducing CR or near CR121. 
As the outcome of transplantation is most promising in the newly diagnosed patients 
without chemorefractory disease, graft contamination and the lack of a survival plateau 
following autologous transplantation, allogeneic transplantation deserve investigation as 
the upfront therapy in the management of patients with MCL92. 
Patients over age 65, and individuals who are not eligible for ASCT with poor prognostic 
MIPI scores remain as a major challenge for the hematologist. In this group of patients, 
promising new drugs such as bendamustine, cladribine and bortezomib in combination 
with synergizing agents such as rituximab, may be offered to patients in the context of 
clinical trials. One should remember that ASCT with intermediate dose melphalan at doses 
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between 100 to 140 mg/m2 can still be utilized in patients over age 65, as well as non-
myeloablative allogeneic stem cell transplants, immediately after achieving a clinical 
complete response in experienced transplant centers. These approaches have to be tested in 
clinical trials in the near future. 
10. Rational approaches in managing patients with MCL 
Due to heterogeneity of disease, paucity of randomized trials, availability of a wide range of 
chemotherapy regimens including new agents, and altering prognostic factors among 
patients, an individualized treatment approach should be adapted for each patient 
diagnosed with MCL. As in therapy of patients with myeloma, long term survival may be 
achieved following sequential and risk-adapted use of available therapies such as intensive 
or nucleoside analogue based chemotherapy, followed by autologous and/or reduced 
intensity allogeneic transplantation, including radioimmunotherapy. 
Rational strategy at present can be outlined as; 
1. After assessing the MIPI score, low risk patients can be followed without 
transplantation strategy, because of late age of onset, which is over 60 in most patients. 
This group of patients will do well with standard chemotherapy regimens utilized in 
NHLs, such as R-CHOP or new generation combination regimens including a purine 
analogue and rituximab, such as R-FCM or FCR. 
2. Due to its poor prognosis and failure to achieve improved survival curves with 
conventional chemotherapy regimens, consideration should be given to upfront 
autologous transplantation in patients with high MIPI scores. To induce remission FCR, 
R-hyperCVAD and R-CHOP-14 regimens seem to be effective approaches. Inducing high 
quality complete responses -molecular remission for t(11;14) translocation-  prior to 
autologous transplantation may further improve disease free and overall survival curves. 
Success of this strategy has been shown in comparison to historical controls, and also has 
to be proven in randomized clinical trials. 
3. Young patients with intermediate MIPI scores may choose to continue with the same 
approach with the ones with high scores as described above. Elderly patients may 
receive R-CHOP, R-FCM or FCR as the initial therapy.   
4. Patients having recurrence following conventional chemotherapy or an autologous 
transplant and who are determined to be fit for an allogeneic transplant following a 
careful evaluation and screening tests should be given a chance to have this treatment 
option to achieve cure. 
5. Regardless of the MIPI score, patients who are not eligible for high dose therapy and 
autologous stem cell support and relapsing after conventional chemotherapy regimens 
and not a candidate for an allogeneic transplant may be treated with bendamustine and 
cladribine containing regimens in the context of clinical trials. 
Transplant strategy can be summarized as; 
Patients with predicted poor survival by MIPI score should undergo intensive induction 
regimens if eligible, to achieve CR, followed by ASCT preferably in first remission. If cure is 
targeted, especially in young patients, allogeneic SCT may be performed following an 
excellent cytoreduction with ASCT or intensive chemotherapy regimen including high dose 
Ara-C and rituximab, such as R-HDS or hyper-CVAD regimens. 
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11. Emerging new drugs to improve results in the near future 
New agents which may have potential to improve outcome of relapsed or refractory 
patients with MCL include chemicals targeting cyclin D1 and the cell cycle regulatory 
proteins (cdk), inhibitors of mammalian target of rapamycin, the proteasome, and 
proapoptotic family members122. 
Both histone deacetylase (HDAC) and mTOR inhibitors may downregulate cyclin D1 
reducing cell cycle drive, which is upregulated in patients with MCL. Cyclin D1 is the key 
factor for upregulating cellular proliferation rate22. HDAC inhibitor sueroylanilide 
hydroxamic acid (vorinostat) has ability to reduce intracellular cyclin D1 levels in MCL cells, 
leading to inhibition of progression to S-phase in the cell cycle, and may induce response in 
MCL patients, currently being tested in phase I clinical trials123. Cyclin D1 protein itself can 
be used as a target for sensitized T-cells, generating a potential treatment option by cellular 
therapy124. 
Other than overexpression of cyclin D1, activation of mammalian target of rapamycin 
(mTOR) also plays a major role in growth and proliferation in MCL cells125. Inhibitiors of 
mTOR (rapamycin, temsirolimus, everolimus) may increase apoptosis and decrease 
proliferation rate by causing G1 arrest in the cell cycle126. Single agent temsirolimus has been 
shown to have clinical activity in phase II trials, and a randomized phase III trial127-129. 
Alternative mTOR inhibitor everolimus is currently in phase II trials130, 131. 
Deficiencies  of Noxa and Bim proteins and aberrant expression of Bcl-2 may reduce 
apoptosis and lead to increased resistance to chemotherapeutic agents132. Proteasome 
inhibitors such as bortezomib and flavopiridol may function as accumulating cdk inhibitors 
(p21/p27), causing cell cycle arrest in malignant cells132-134. Accumulation of proapoptotic 
Noxa protein has been consistently shown in MCL cells treated with bortezomib135. 
There is a rationale combining bortezomib with HDAC inhibitor vorinostat.  Vorinostat may 
be able to turn off cyclin D1, whereas bortezomib turns on cdk inhibitors p27 and p21, 
targeting two complementary genetic lesions involved in the cell cycle aberration in MCL 
cells which may lead to induction of apoptosis136. Bortezomib may also be combined with 
cyproheptadine, recently identified inhibitor of cyclin D1, synergistic in inducing apoptosis 
in vitro137. 
Development of new drugs for MCL will further improve the recent achievements in the 
management options published in the last decade, in a disease currently not curable by 
medical therapy except allogeneic transplantation. 
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